| Name | Title | Contact Details |
|---|
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Developing the next generation of immuno-oncology therapeutics
InVitria is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Oxford Finance Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
FASgen is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.